These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

892 related articles for article (PubMed ID: 34579068)

  • 1. The Effect of Probiotics (MCP
    Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease.
    Ayob N; Muhammad Nawawi KN; Mohamad Nor MH; Raja Ali RA; Ahmad HF; Oon SF; Mohd Mokhtar N
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Probiotics and
    Wang W; Xu AL; Li ZC; Li Y; Xu SF; Sang HC; Zhi F
    Diabetes Metab J; 2020 Apr; 44(2):336-348. PubMed ID: 31950772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multi-strain Probiotic Reduces the Fatty Liver Index, Cytokines and Aminotransferase levels in NAFLD Patients: Evidence from a Randomized Clinical Trial.
    Kobyliak N; Abenavoli L; Mykhalchyshyn G; Kononenko L; Boccuto L; Kyriienko D; Dynnyk O
    J Gastrointestin Liver Dis; 2018 Mar; 27(1):41-49. PubMed ID: 29557414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer.
    Zaharuddin L; Mokhtar NM; Muhammad Nawawi KN; Raja Ali RA
    BMC Gastroenterol; 2019 Jul; 19(1):131. PubMed ID: 31340751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative experimental investigation on the efficacy of mono- and multiprobiotic strains in non-alcoholic fatty liver disease prevention.
    Kobyliak N; Falalyeyeva T; Virchenko O; Mykhalchyshyn G; Bodnar P; Spivak M; Yankovsky D; Beregova T; Ostapchenko L
    BMC Gastroenterol; 2016 Mar; 16():34. PubMed ID: 26976285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
    Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial.
    Ebrahimi-Mousavi S; Alavian SM; Sohrabpour AA; Dashti F; Djafarian K; Esmaillzadeh A
    BMC Gastroenterol; 2022 Mar; 22(1):102. PubMed ID: 35255811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation.
    Zhao Z; Chen L; Zhao Y; Wang C; Duan C; Yang G; Niu C; Li S
    Appl Microbiol Biotechnol; 2020 Jun; 104(12):5273-5282. PubMed ID: 32335723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
    Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis.
    Liu X; Sun R; Li Z; Xiao R; Lv P; Sun X; Olson MA; Gong Y
    Arch Biochem Biophys; 2021 Oct; 711():109019. PubMed ID: 34478730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.
    Jiang W; Wu N; Wang X; Chi Y; Zhang Y; Qiu X; Hu Y; Li J; Liu Y
    Sci Rep; 2015 Feb; 5():8096. PubMed ID: 25644696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blocking integrin α
    Rai RP; Liu Y; Iyer SS; Liu S; Gupta B; Desai C; Kumar P; Smith T; Singhi AD; Nusrat A; Parkos CA; Monga SP; Czaja MJ; Anania FA; Raeman R
    J Hepatol; 2020 Nov; 73(5):1013-1022. PubMed ID: 32540177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol.
    Silva-Sperb AS; Moraes HA; de Moura BC; Alves BC; Bruch-Bertani JP; Azevedo VZ; Dall'Alba V
    Trials; 2019 Oct; 20(1):580. PubMed ID: 31601229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Childs CE; Del Fabbro S; Bilson J; Moyses HE; Clough GF; Sethi JK; Patel J; Wright M; Breen DJ; Peebles C; Darekar A; Aspinall R; Fowell AJ; Dowman JK; Nobili V; Targher G; Delzenne NM; Bindels LB; Calder PC; Byrne CD
    Gastroenterology; 2020 May; 158(6):1597-1610.e7. PubMed ID: 31987796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
    Kessoku T; Imajo K; Kobayashi T; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Saito S; Nakajima A
    Contemp Clin Trials; 2018 Jun; 69():40-47. PubMed ID: 29627620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probiotics may be useful for drug-induced liver dysfunction in patients with depression - A secondary analysis of a randomized clinical trial.
    Gawlik-Kotelnicka O; Burzyński J; Rogalski J; Skowrońska A; Strzelecki D
    Clin Nutr ESPEN; 2024 Oct; 63():604-614. PubMed ID: 39089652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier.
    Zhou D; Pan Q; Xin FZ; Zhang RN; He CX; Chen GY; Liu C; Chen YW; Fan JG
    World J Gastroenterol; 2017 Jan; 23(1):60-75. PubMed ID: 28104981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.